Abstract: The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymel nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.

Abstract: The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymal nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.

Abstract: The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymel nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.

Abstract: According to the present invention, S100A4 protein also known as Mts-1 interferes with the function of Annexin 2 and Annexin2/P11 tetramer by binding to Annexin 2. The present inventors have demonstrated that binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering with Annexin 2 mediated tissue plasminogen activator (tPA) dependant conversion of plaminogen into plasmin and further conversion of plasmin into angiostatins. The present invention has further identified that the S100A4 protein binds to the N-terminal region of Annexin 2.